EGFR and head and neck squamous cell carcinoma: A phase I/IIa, first-in-human, open-label, multicenter study of EGFR-targeted NIR-PIT using a cetuximab-IR700 conjugate (RM-1929) was completed with tolerable and manageable side effects in patients with heavily pretreated recurrent HNSCC [20].